"If you don't learn or understand the big model of AI, you will be abandoned by social development." Recently, Chen Runsheng, an academician of the CAS Member and a bioinformatics, said in his keynote report at the Multi group Forum on Big Data and Medical Development at the 26th annual meeting of the Chinese Association for Science and Technology. The "China Artificial Intelligence Large Model Map Research Report" released by institutions such as the New Generation Artificial Intelligence Development Research Center of the Ministry of Science and Technology in 2023 shows that the number of large models developed in China ranks second in the world. More and more companies are entering the field of artificial intelligence big model development. Artificial intelligence big models are ushering in a technological revolution, and medical research is an important field for the application of big models. Chen Runsheng mentioned the "Tianhe · Lingshu" big model developed in China, which is a professional big model oriented to the field of acupuncture and moxibustion in traditional Chinese medicine. It is developed based on professional data such as classic works of traditional Chinese medicine, acupuncture and moxibustion clinical evidence-based evidence database and evidence-based knowledge map of traditional Chinese medicine. There are also cases of artificial intelligence models being implemented in the medical field internationally. For example, DeepMind, an artificial intelligence company under Google, has trained an artificial intelligence algorithm by processing a large number of retinal scan images. Compared to human doctors, this algorithm can detect retinal diseases more efficiently and accurately. Chen Runsheng said that precision medicine research has become a strategic high ground in the new round of national scientific and technological competition, and its foundation is biomedical data. According to literature reports, the biomedical data infrastructure mainly based on "clinical+multi omics" supports more than 2/3 of the original drug research and development work approved by the US Food and Drug Administration, and receives huge industry returns every year. In the eyes of industry experts, shifting from phenomenon driven to data-driven is a major trend in medical research. Wang Yongjun, Dean of Beijing Temple of Heaven Hospital affiliated with Capital Medical University, said that large-scale cohort studies based on a large population will provide important data support for biomedical models. In addition to being used for discovering new drug targets, big data can also be used for conducting simulation experiments. Wang Xiujie, a researcher at the Institute of Genetics and Developmental Biology of the Chinese Academy of Sciences, believes that the continuous emergence of a large number of data provides opportunities for medical research to obtain new discoveries. At the same time, the lack of clinical data, personal privacy protection, and data supervision issues also pose challenges to the scientific and rational use of medical data. She suggested that experimental biologists and clinical physicians should master data analysis skills, ensure sufficient communication, and better leverage the driving role of big data. (New Society)